COMP <GO>
CABA vs LCTX // EV/EBITDA & P/E VALUATION
Cabaletta Bio Inc. (NASDAQ) VS. Lineage Cell Therapeutics Inc. (NYSE) • 15-METRIC TALLY: CABA 1
— LCTX 2
■ METRIC PARITY
LAST: $1.59 (+4.28%) • MKT CAP: $268.7M
valuation
—
LAST: $1.03 (-0.96%) • MKT CAP: $260.5M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CABA VS. LCTX)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CABA | LCTX | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | -7.46% | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | -60.00% | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | -60.00% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | 53.20% | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 0.20 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 2/9 | 3/9 | -1.00 | LCTX | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 37.1 | 50.8 | -13.67 | LCTX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $268.7M | $260.5M | $8.2M | CABA | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CABA REV | LCTX REV | CABA GROSS % | LCTX GROSS % | CABA FCF | LCTX FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $14.6M | — | — | -$132.3M | -$19.4M |
| FY 2024 | $0 | $9.5M | — | 96.5% | -$90.4M | -$23.7M |
| FY 2023 | $0 | $8.9M | — | — | -$53.5M | -$28.6M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CABA // BETA —
LCTX // BETA —